dermatitis skin News
-
Evolve BioSystems, Inc. Announces Collaboration with Janssen to Study the Impact of B. infantis EVC001 in the Reduction of Atopic Dermatitis
Evolve BioSystems, Inc., a global leader dedicated to improving human health through the gut microbiome, today announced a collaboration with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to conduct a clinical study in children at risk for developing atopic dermatitis. The study will assess the effects of introducing a specific gut ...
-
RECELL System Vitiligo Clinical Trial Protocol to be Presented at the Global Vitiligo Foundation Annual Scientific Symposium
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that an abstract highlighting the clinical trial protocol utilizing the RECELL® Autologous Cell Harvesting Device (RECELL® System) to treat vitiligo will ...
-
Accurate detection of Glutaraldehyde
The Glutaraldemeter 3 by PPM Technology is an easy-to-use, portable instrument that employs an electrochemical sensor to indicate levels of glutaraldehyde vapor in air. The instrument provides a rapid direct read-out of vapor levels on an LCD display, making it a useful screening tool to complement existing routine chemical glutaraldehyde monitoring techniques. User friendly and easy to ...
-
RECELL System to be Highlighted at Upcoming Music City SCALE Multidisciplinary Dermatology Meeting
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that a discussion on the RECELL System will be held during the Symposium for Cosmetic Advances & Laser Education (SCALE) multidisciplinary ...
-
Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders
Neuropathix, Inc. (“Neuropathix” or the “Company”) (OTCQB:NPTX), a socially responsible pain management life sciences company, announced today the publication of the global Patent Cooperation Treaty (PCT) Patent under Publication No. WO/2021/097351 “Functionalized 1,3-Benzene Diols and Their Method of Use for the Treatment of Radiation Dermatitis and Other Skin ...
-
New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis
Low dose arm of the study met the co-primary endpoints of percent change in Eczema Area and Severity Index (EASI) score from baseline, and incidence of treatment-emergent adverse events, through week 16 First trial to assess the effects of blocking OX40-Ligand, a key immune system regulator, in patients with moderate-to-severe atopic dermatitis Data support amlitelimab as a potential ...
-
What needs to notice when choosing laser hair removal treatment
Why remove hair? Everyone wants their skin to be clean and fair, but some women have thick body hair and dare not wear skirts, especially in summer, when people show their bodies. Because of the thick hair on their bodies, it has a great impact on their overall image and is easy to give to them. Their psychology has caused a great shadow. Some women have thick and slender lip hair, which looks ...
-
How to adjust the spray bottle into a mist
Press the gas first, maybe the air pressure is not enough. If the air pressure is sufficient, adjust the plastic screw at the front end of the nozzle. In the spray can, the liquid and a gas which can be ejected by the fine particles are stored under a pressurized state. In the past, a gas called a chlorofluorocarbon was placed in a spray can, which was harmful to the environment. Many spray ...
-
Successful development and approval of Skinatan® 1 mg/g Emulsion – a new generic drug for the treatment of inflammations and allergic reactions
Skin Care Pharma GmbH, a company of Dermago Verwaltungs GmbH, announces that yet another milestone has been reached in the development and approval of Skinatan 1 mg/g Emulsion for cutaneous application with the active ingredient methylprednisolone aceponate (MPA). Upon receipt of the “End of Procedure” notification, the decentralized procedure (DCP) for Skinatan 1 mg/g Emulsion has ...
-
Formaldehyde in Clothes, is it Cause for Health Concerns?
LA Testing provides formaldehyde and VOC testing services to ensure consumer products such as clothing, as well as indoor environments, are safe for building occupants. Garden Grove, CA, October 5th, 2010 Textile resins containing formaldehyde have been used in some clothing since the 1920s. The formaldehyde in the resins helps to make the clothing wrinkle and stain resistant, but these ...
-
DermBiont Announces Positive Results in Phase 2a Clinical Trial in Atopic Dermatitis with a Topical Live Biotherapeutic
BOSTON, Jan. 8, 2021 /PRNewswire-PRWeb/ -- DermBiont, a clinical-stage biotechnology company developing targeted topical therapeutics, - announced today that its Phase 2a clinical trial with its investigational drug product, DBI-001, in atopic dermatitis, has demonstrated decreases in the abundance in S. aureus, improvement in signs and symptoms of atopic dermatitis, and no safety or ...
-
Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company’s Over-The-Counter Cosmeceutical Assets
Cosmeceutical Assets Include Company’s Lead Anti-inflammatory OTC Cosmeceutical Compound called LEA™ (Limonenyldihydroxybenzyl Ethoxycarbonyl Azetidine) Company’s Strategy is to Enable Dermique to Focus on Commercializing Near Term Revenue Drivers like LEA™, Other Cosmeceuticals DOYLESTOWN, PA / ACCESSWIRE / August 24, 2021 / Neuropathix, Inc. (“Neuropathix” ...
-
Nature Scientific Reports has published a peer reviewed paper showing important immune response benefits associated with AOBiome`s B244 Ammonia Oxidizing Bacteria drug therapy
B244 inhibits Th2 immune polarization in human primary immune cells in both the active and the inactive state. CAMBRIDGE, Mass., July 15, 2021 /PRNewswire/ — AOBiome Therapeutics, Inc. (“AOBiome”), a leading clinical-stage microbiome company focusing on inflammatory conditions, announced new findings indicating a link between Ammonia Oxidizing Bacteria (AOB) and the human ...
-
DermBiont Announces Acquisition of SeylanMED to Expand its Portfolio of Targeted Topical Therapeutics Treating Skin Diseases at Their Root Cause
BOSTON, MA, October 21, 2020 – DermBiont, Inc., a clinical stage precision dermatology company targeting skin diseases at their root cause has expanded its pipeline and therapeutic modalities with the acquisition of SeylanMED, Inc. “This strategic acquisition delivers multi-factorial value,” said Karl Beutner, MD, PhD, Co-founder, CEO, and CMO of DermBiont. “It expands ...
-
AOBiome Therapeutics Expands Intellectual Property Estate with Issuance of U.S. Patent for Use of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Eczema
AOBiome Therapeutics, Inc. (“AOBiome”), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering the use of the Company’s Ammonia ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you